A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications.
Lay Description
To assess the efficacy of ABBV-400 in each solid tumor indication, including advanced or metastatic hepatocellular (HCC), biliary tract cancer (BTC), pancreatic ductal adenocarcinoma (PDAC), esophageal squamous cell carcinoma (ESCC), triple negative (TN) breast cancer (BC), hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) BC, and head and neck squamous cell carcinoma (HNSCC). The purpose of this study is to evaluate ABBV-400 in subjects with select solid tumors. This study will consist of multiple cohorts with each cohort investigating ABBV-400 at 3 mg/kg Q3W.
Category
- Cancers and Other Neoplasms
- Carcinoma
- IRB Number
- STUDY00000115
- NCT Number
- NCT # not yet entered
Eligibility
- Eligible Ages
- 18-99
- Eligible Genders
- All
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Frances Crawford
210-450-5037
crawfordf1@uthscsa.edu
Myrna Montenegro
210-450-5954
montenegro@uthscsa.edu
Kathleen Rodriguez
210-450-1365
rodriguezk3@uthscsa.edu
Benjamin Schleif
210-450-1366
schleifb@uthscsa.edu
Morgan Seekatz
210-450-1133
seekatz@uthscsa.edu
Jessica Villarreal
villarreal24@uthscsa.edu
Principal Investigator
Daruka Mahadevan